natgillin/translations-raw huggingface dataset:
testing the immunogenicity of each optimized epitope obtained in step (iii), in an appropriate model, and selecting those which are immunogenic; 
(V) ispitivanje imunogeničnosti svakog optimiranog epitopa dobivenog u koraku (iv), u HLA-A*2402 transgeničnog miša, i odabir onoga koji je imunogeničan;
is the number of potency measurements 
(21) Broj predmeta:
The formulation for use according to claim 5 wherein the compound of formula (I) is administered to the subject in doses of 100 mg two times a day. 
Formulacija za primjenu u skladu sa patentnim zahtjevom 5 pri čemu spoj sa formulom (I) je administrirano subjektu u dozama od 100 mg dva puta na dan.
wherein the wound is selected from the group consisting of dry wounds and wounds needing additional moisture, and 
Zavoj za ranu prema bilo kojem od prethodnih zahtjeva, naznačen time da je rana (18) odabrana iz skupine koja se sastoji od suhih rana ili rana s malim izlučivanjem tekućine za ranu.
A compound of claim 2, wherein: 
Spoj patentnog zahtjeva 2, gdje:
The method for the preparation of the agomelatine hydrochloride hydrate according to claim 4 or 6, wherein said organic solvent is ethyl acetate, methyl acetate, n-butyl acetate, acetone or acetonitrile. 
Postupak za dobivanje agomelatina hidroklorid hidrata u skladu s patentnim zahtjevom 4 ili 6, naznačen time, da je organsko otapalo etil-acetat, metil-acetat, n-butil acetat, aceton ili acetonitril.
u is an integer from 1 to 10 and can also be 0, 
• u je cijeli broj od 1 do 10, a također može biti i 0;
The blister pack according to claim 1, in which said shaped layer comprises at least one layer of polymer material. 
Blister pakiranje prema 1. zahtjevu, naznačeno time da navedeni oblikovani sloj (8) sadrži najmanje jedan sloj polimerskog materijala (82).
The aqueous formulation of any of the foregoing claims comprising 90 µg/mL zinc, 2.7 mg/mL m-cresol and 20 mg/mL glycerol 85%. 
Vodena formulacija u skladu s patentnim zahtjevom 6, naznačena time što sadrži 90 mg/ml cinka, 2,7 mg/ml m-krezola i 20 mg/ml 85%-tnog glicerola.
A pharmaceutical composition for the prevention or treatment of obesity, comprising the conjugate of any one of claims 1 to 17. 
Farmaceutski sastav za prevenciju ili liječenje pretilosti, koji sadrži konjugat prema bilo kojem od zahtjeva 1 do
In yet another preferred aspect of the present invention the composition contains dimethylfumarate at a dose range of 125 mg to 500 mg and laquinimod at a dose range of 0.05 mg to 0.25 mg. 
(b) dimetilfumarat u rasponu doze od 125 mg do 500 mg i lakvinimod u rasponu doze od 0,05 mg do 0,25 mg.
Thus, according to another aspect the invention provides a pharmaceutical composition, wherein at least one peptide includes non-peptide bonds. 
2. - Peptid u skladu s patentnim zahtjevom 1, pri čemu navedeni peptid uključuje nepeptidne veze.
The pharmaceutical composition of item 14 suitable for a dosing schedule from once every 2 weeks to once monthly. 
Farmaceutski pripravak prema zahtjevu 1 ili 2, koja je prikladan za doziranje rasporeda od jednom svaka 2 tjedna do jednom mjesečno.
The method according to claim 1, wherein the excess steam passes at least one separator to remove any carried particulate matter from the excess steam before it is fed as purified and/or reboiled excess steam into at least one mechanical compressor. 
Postupak u skladu s bilo kojim od prethodnih zahtjeva, naznačen time da višak pare (7) prolazi barem kroz jedan separator (44) kako bi se uklonile bilo koje prenesene čestice iz viška pare prije nego se dovede kao pročišćeni ili ponovno prokuhani višak pare (17) u barem jedan mehanički kompresor (43).
Mobile fuel distribution station 
POKRETNA POSTAJA ZA DISTRIBUCIJU GORIVA
The compound as claimed in claim 7 in crystalline form, characterised by an X-ray powder diffraction pattern (XRPD) with at least two specific peaks at 2-theta = 8.4° and 10.9° wherein said values may be plus or minus 0.2° 2-theta. 
Spoj prema zahtjevu 7 u kristalnom obliku, naznačen time da ima uzorak difrakcije X-zraka na prahu (XRPD) s barem dva specifična maksimuma 2-theta = 8.4* 1 10.9" pri čemu navedene vrijednosti mogu biti plus ili minus 0.2* 2-theta.
The control surface element according to claim 14, wherein a height and/or width of said secondary reinforcing elements arranged in the V-shape diminishes towards the rear longitudinal edge of said composite fiber element. 
Površinski upravljački element (4) prema zahtjevu 8, naznačen time, da se visina i/ili širina od sekundarnih potpornih elemenata (11') koji su raspoređeni u obliku slova V, smanjuje prema stražnjem uzdužnom bridu od vlaknastog spojnog elementa (3).
allowing the mouse to develop an immune response to the antigen; and isolating from the mouse of (b) an antibody that specifically recognizes the antigen, or isolating from the mouse of (b) a cell comprising an immunoglobulin domain that specifically recognizes the antigen, or identifying in the mouse of (b) a nucleic acid sequence encoding a heavy and/or light chain variable domain that binds the antigen, wherein the antibody comprises a light chain derived from a hVλ a hJλ and a mouse Cλ gene. 
Postupak za izradu antitijela u mišu koji se sastoji od a) b) izlaganja miša prema bilo kojem zahtjevu od 1 do 10ili 17 antigenu; puštanja miša da razvije imunološki odgovor na antigen; i izoliranja iz miša (b) antitijela koje specifično prepoznaje antigen ili izoliranja iz miša (b) stanice koja se sastoji od imunoglobulinske domene koja posebno prepoznaje antigen, pri čemu antitijelo sadrži lanac dobiven iz humanog VA segmenta gena, humanog JA segmenta gena i mišjeg CK gena.
ITEMS A lipid having a structural Formula (I): 
Lipid, naznačen time, da ima strukturnu formulu (1):
The stabilizer is selected from the group consisting of L-phenylalanine, trans-cinnamic acid and benzoic acid. 
Farmaceutski sastav iz bilo kojeg od patentnih zahtjeva 1-3, pri čemu je stabilizator benzojeva kiselina.
represents a group represented by the following formula 
predstavlja grupu predstavljenu sljedećom formulom [Kem. 25] [image]
The solid dosage form of paragraph 9, wherein the polymorph of Formula I is present in at least about 85% of the total weight. 
Farmaceutski pripravak u skladu s patentnim zahtjevom 3, naznačen time što je polimorf Formule I prisutan u najmanje 85% od ukupne težine, te gdje je farmaceutski pripravak u čvrstom obliku doziranja.
The use of a lipochitooligosaccharide of formula (I) as defined in claim 1 or claim 2 as an additive for production of an arbuscular mycorrhizal inoculant. 
Uporaba smjese lipokitooligosaharida iz bilo kojeg od patentnih zahtjeva 1 do 2 kao dodatka za proizvodnju arbuskularno mikoriznog inokulanta.
A closed loop system for controlling blood glucose levels in a subject, comprising: a fast-acting insulin analog selected from insulin aspart or insulin glulisine; and 
Sustav sa zatvorenim krugom za kontrolu nivoa glukoze u krvi kod subjekta, koji sadrži: brzo djelujući analog inzulina, pri čemu je brzo djelujući analog inzulina inzulin glulizin ili inzulin aspart, i enzim koji razgrađuje hijaluronan;
In the method 100, the metabolic modulator/penetrant is selected from the group consisting of polar aprotic solvents, DMSO, Acetone, N,N-Dimethylformamide, or Acetonitrile. 
Postupak prema zahtjevu 10, naznačen time da je metabolički modulator odabran iz skupine koja sadrži polarna aprotička otapala, DMSO, aceton, N,N-dimetilformamid, i acetonitril.
A method of treating dystonia, extrapyramidal effects, dysphagia, rigidity and/or stiffness of limbs, choreoathetosis, tremor, dementia, spasticity, muscle weakness, or seizure in a subject, the method comprising administering to the subject an effective amount of a compound of claim 1 . 
Spoj u skladu s patentnim zahtjevom 7, naznačen time što se patologiju bira između distonije, ekstrapiramidalnih učinaka, disfagije, krutosti i/ili ukočenosti udova, koreoatetoze, tremora, demencije, spazama, mišićne slabosti, te napadaja.
A process for the preparation of a compound of Formula (I) according to claim 1, wherein G is an alkyl, acyl, phosphoryl or sulfonyl group, which comprises treating the compound of the formula (A) wherein R1, R2, R3, R4, R5, R6, R7, R8 and X have the meanings assigned to them in claim 1 with a compound of the formula G - Y, wherein G represents the alkyl, acyl, phosphoryl or sulfonyl group to be incorporated and Y is a suitable nucleofuge, in the presence of at least one equivalent of a base. 
Postupak priprave spoja formule (I) prema zahtjevu 1, pri čemu G je alkil, acil, fosforil ili sulfonil skupina, naznačen time, da obuhvaća tretiranje spoja formule (A) Formula (A) gdje R!, RR", R', RR. R', Rši X imaju značenja koja su im naznačena u zahtjevu 1, sa spojem formule G -Y, gdje G predstavlja alkil, acil, fosforil ili sulfonil skupinu koja se treba pripojiti, a Y je pogodna nukleofuga, u prisutnosti barem jednog ekvivalenta baze.
The method of any of the previous claims, whereby said molecule comprises the nucleotide sequence 5'- UCAGCUUCUGUUAGCCACUG (Seq ID NO 5). 
"Nekodirajući oligonukleotid sastoji se od slijeda 5' ucagcuucuguuagccacug 3' (SEQ ID NO;5).
(viii) at least 30% of the cells in the population express on their surfaces detectable levels of epidermal growth factor receptor (EGF-R), 
(vili) najmanje 30 % stanica u populaciji na svojoj površini izražava uočljive razine receptora epidermalnog faktora rasta (EGF-R),
Indeed, in certain embodiments, the composition is for use in a method of reducing a neutrophilic inflammatory response in the treatment or prevention of asthma, or the composition is for use in a method of reducing an eosinophilic inflammatory response in the treatment or prevention of asthma. 
Pripravak za upotrebu prema zahtjevu 2, naznačen time što je pripravak za upotrebu u postupku liječenja ili sprečavanja astme, kao što je neutrofilna astma 1li alergijska astma 1 pri čemu je pripravak za upotrebu u postupku smanjenja neutrofilije ili eozinofilije za liječenje astme.
1, 2, 16, and 21 for use in a method of treatment of depression, atypical depression, bipolar disorders, anxiety disorders, obsessive-compulsive disorders, social phobias or panic states, sleep disorders, sexual dysfunction, psychoses, schizophrenia, migraine and conditions associated with cephalic pain or other pain, raised intracranial pressure, epilepsy, personality disorders, age-related behavioral disorders, behavioral disorders associated with dementia, organic mental disorders, mental disorders in childhood, aggressivity, age-related memory disorders, chronic fatigue syndrome, drug and alcohol addiction, obesity, bulimia, anorexia nervosa or premenstrual tension of the human or animal body by therapy. 
Spoj u skladu s bilo kojim zahtjevom 1 do 11, naznačen time, da se koristi u postupku liječenja depresije, atipične depresije, bipolarnog poremećaja, anksioznosti, opsesivno-kompulsivnog poremećaja, socijalne fobije ili stanja panike, poremećaja spavanja, seksualne disfunkcije, psihoza, šizofrenije, migrene ili stanja povezanih s glavoboljom ili ostalom boli, povećanog intakranijalnog tlaka, epilepsije, poremećaja osobnosti, poremećaja ponašanja povezanih sa dobi, poremećaja ponašanja povezanih sa demencijom, organskih mentalnih poremećaja, mentalnih poremećaja u djetinjstvu, agresivnosti, poremećaja pamćenja povezanih s dobi, sindroma kroničnog umora, odvikavanja od droga ili alkohola, debljine, bulimije, anoreksije nervoze ili predmenstrualne napetosti.
In a first aspect, the present invention provides a fluorocarbon vector-antigen construct having a chemical structure CmFn—CyHx-(Sp)-R or derivatives thereof, where m=3 to 30, n<=2m+1, y=0 to 15, x<=2y, (m+y)=3-30 and Sp is an optional chemical spacer moiety and R is an antigen derived from the influenza virus. 
Farmaceutski pripravak prema bilo kojem od zahtjeva 2 do 5, naznačen time, da nadalje obuhvaća više konstrukcija fluorugljičnog vektora i antigena strukture CmFn-Cy-Hx-(Sp)-R ili njihove derivate, pri čemu je m = 3 do 30, n <= 2m +1, y = 0 do 15, x <= 2y, (m + y) = 3-30, Sp je dodatna kemijska razdvajajuća skupina, a R je peptid virusa gripe.
A synergistic combination according to claim 1, wherein the phenoxybenzamine is phenoxybenzamine hydrochloride. 
2. < Kombinacija prema zahtjevu 1, naznačena time da fenoksibenzamin je fenoksibenzamin hidroklorid.
A compound of any one of claims 1 to 12 for use in a method for preventing, inhibiting, or treating the progression or onset of diseases or disorders associated with the activity of the GPR 119 G protein-coupled receptor and, optionally, further using an additional therapeutic agent wherein: 
Spoj prema zahtjevu 19 i, izborno, dodatno terapijsko sredstvo za uporabu u postupku modulacije aktivnosti GPR11 G-protein-vezanog receptora, postupak obuhvaća davanje učinkovite količine gornjjeg spoja, bolesniku sisavcu kod kojeg postoji potreba.
The crude product was added NaOH (1M) and extracted with ethyl acetate. 
Krutom produktu se doda NaOH (1M) i ekstrahira se s etil acetatom.
The device according to the preceding claim, characterized in that it is provided with self-adhesive means for enabling installation thereof in a convenient and stable position on the windscreen. 
Uređaj u skladu s prethodnim patentnim zahtjevom, naznačen time što je koje ima samoljepivo sredstvo koje omogućuje njegovu ugradnju u pogodnom 1 stabilnom položaju na vjetrobramu.
a nucleic acid sequence encoding (i) the amino acid sequence of SEQ ID NO: 7, (ii) an amino acid sequence having at least 70% identity with the amino acid sequence of SEQ ID NO: 7, or (iii) an amino acid sequence that differs in 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11 or 12 amino acids from the amino acid sequence of SEQ ID NO: 7; or 
sekvence nukleinske kiseline koja kodira (i) aminokiselinsku sekvencu SEQ ID NO: 32, (ii) aminokiselinsku sekvencu koja ima najmanje 75% identičnosti sa aminokiselinskom sekvencom iz SEQ ID NO: 32, ili (iii) aminokiselinsku sekvencu koja se razlikuje u 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11 ili 12 aminokiselina od aminokiselinske sekvence iz SEQ ID NO: 32; ili
The antibody of claim 1, wherein the VH comprises the amino acid sequence of SEQ ID NO: 99, or having 1, 2 or 3 amino acid substitutions in the VH of SEQ ID NO: 99. 
Protutijelo sukladno patentnom zahtjevu 2, naznačeno time, da: VL sadrži sekvence aminokiselina od SEK ID BR-a: 62 ili 63; i VH sadrži sekvence aminokiselina od SEK ID BR-a: 64, 65, 66, 101, 102,
The compound of claim 1 or any one of claims 9 to 11, wherein the compound of Formula I is any one of the compounds of the table below, 
Farmaceutski sastav prema zahtjevu 1 ili zahtjevu 10, gdje je spoj formule I bilo koji spoj iz donje tablice, ili njegova farmaceutski prihvatljiva sol.
X and Y are independently selected from hydrogen, optionally substituted (C1-C6)alkyl, optionally substituted (C3-C8)cycloalkyl, optionally substituted aryl, optionally substituted heteroaryl or optionally substituted heterocyclo; 
X i Y su nezavisno odabrani od vodika, po izboru supstituiranog (C1-C6)alkila, po izboru supstituiranog (C3-C8)cikloalkila, po izboru supstituiranog arila, po izboru supstituiranog heteroarila ili po izboru supstituiranog heterociklo;
encoding means for encoding the target frame by the first encoding means after initialization of the adaptive codebook by the initialization means. An audio signal decoding program for decoding an encoded audio signal using first decoding means operating under a linear predictive coding scheme and second decoding means operating under a coding scheme which is different from the linear predictive coding scheme, the audio signal decoding program causing a computer device to function as: 
Kompjutorski program za dekodiranje audio signala koji sadrži naredbe koje, kada ih se provodi na kompjutoru, uzrokuju da navedeni kompjutor dekodira kodirani audio signal uz pomoć prvog dekodera (24), koji radi prema linearnoj prediktivnoj shemi kodiranja, i drugi dekoder (25), koji radi prema shemi kodiranja koja se razlikuje od linearne prediktivne sheme kodiranja, naznačen time što program za dekodiranje audio signala uzrokuje da kompjutorski uređaj funkcionira kao:
The method as recited in claim 1, wherein the electroplating process comprises rotating the barrel on an intermittent basis while the metal layer is electroplated onto the metal substrate. 
Postupak u skladu s patentnim zahtjevom 1, naznačen time što postupak galvaniziranja sastoji uključuje povremeno rotiranje bubnja dok se metalni sloj galvanizira na metalnu podlogu.
A second phase relation is detected between the wiring phase voltage at the relay location and the wiring phase voltage at the remote location. 
- < otkrivanje drugog faznog odnosa između faznog napona vodiča na spomenutoj relejnoj lokaciji i faznog napona vodiča na spomenutoj udaljenoj lokaciji;
an immunoglobulin light chain variable domain (VL) which comprises in sequence hypervariable regions CDR1', CDR2' and CDR3', said CDR1' having the amino acid sequence SEQ ID NO:4, said CDR2' having the amino acid sequence SEQ ID NO:5, and said CDR3' having the amino acid sequence SEQ ID NO:6 or direct CDR' equivalents thereof, 
VL koji obuhvaća u nizu hipervarijabilna područja CDR1’, CDR2’ i CDR3’, gdje navedeno područje CDR1’ ima aminokiselinsku sekvencu SEQ ID NO:4, navedeno područje CDR2’ ima aminokiselinsku sekvencu SEQ ID NO:5, i navedeno područje CDR3’ ima aminokiselinsku sekvencu SEQ ID NO:6, dok su hipervarijabilna područja određena prema Kabat-definiciji.
iii) hydrolyzing a compound of formula (VII) to obtain a compound of formula (IA). 
(VID) ili) hidroliza spoja formule (VII), pri čemu nastaje spoj formule (IA).
wherein in formula (I) M is selected from the group consisting of X is a spacer, i.e. 
pripravka; pri čemu u formuli (1) M je odabran iz skupine koja se sastoji od X je razmaknica, npr.
A composition according to any one of the preceding embodiments, wherein the amount of said salt of N-(8-(2-hydroxybenzoyl)amino)caprylic acid is up to 2.1 mmol, such as selected from the group consisting of up to 2.1 mmol, up to 2 mmol, up to 1.9 mmol, up to 1.8 mmol, up to 1.7 mmol, up to 1.6 mmol, up to 1.5 mmol, up to 1.4 mmol, up to 1.3 mmol, up to 1.2 mmol and up to 1.1 mmol. 
Kompozicija prema bilo kojem od prethodnih patentnih zahtjeva, naznačena time što je količina navedene soli N- (8-(2-hidroksibenzoil)amino)kaprilne kiseline do 2.1 mmol, kao što je izabrana iz grupe koja se sastoji od do 2.1 mmol, do 2 mmol, do 1.9 mmol, do 1.8 mmol, do 1.7 mmol, do 1.6 mmol, do 1.5 mmol, do 1.4 mmol, do 1.3 mmol, do 1.2 mmol 1 do 1.1 mmol.
30 for the quantitation of DNA sequences from turkey (Meleagris gallopavo); or primers comprising or consisting of the sequences of SEQ ID NOs. 
30 za kvantifikaciju DNK sekvenci puretine (Meleagris gallopavo); ili 2) = početnice sadržeći ili sastojeći se od sekvenci SEQ ID NOs.
2010/2011 seasonal influenza vaccine strains were grown using the MDCK-derived cells under the following suspension culture conditions: 
(d) kulturiranje zaraženih uzgojenih MDCK-deriviranih stanica pri uvjetima koji omogućuju kloniranje virusa gripe; te
It is also an embodiment of the present invention the use of b) an M3 antagonist of the invention and (a) a corticosteroid without any other active compound for the preparation of a medicament for simultaneous, concurrent, separate or sequential use in the treatment of a respiratory disease which responds to M3 antagonism in a human or animal patient. 
Sljedeće je utjelovljenje predmetnog izuma uporaba b) M3 antagonista sukladno predmetnom izumu i (a) B2 agonista bez ikakvog drugog djelatnog spoja za pripravu lijeka za istovremenu, paralelnu, odvojenu ili sekvencijalnu uporabu u liječenju respiratornih bolesti koje odgovaraju na M3 antagonizam u bolesnih ljudi ili životinja.
the chemical modification comprises an end blocking modification of a 3' untranslated region of the mRNA; 
(ili) kemijska modifikacija podrazumijeva modifikaciju tipa bloka kraja 3' netranslatirajuće regije IRNK;
For Formula I compounds, R1 is selected from the group consisting of —OH, ORa, and NRbRc. 
R! je odabran iz skupine koju čine -OH, OR*, i NR*R";
The reaction mixture was allowed to come to room temperature and was stirred at this temperature over night. 
Reakcijska smjesa se ostavi neko vrijeme na sobnoj temperaturi i miješa se na sobnoj temperaturi preko noći.
glycopyrronium bromide at a dosage in the range from 5 to 26 mcg per actuation; 
(a) < glikopironijev bromid u dozi u rasponu od 5 do 26 ug po aktiviranju;
at least one active agent, and at least one polyethylene oxide having, based on rheological measurements, an approximate molecular weight of at least 1,000,000, to yield a first composition for an active agent-containing layer first layer; providing a second composition comprising at least one polyethylene oxide having, based on rheological measurements, an approximate molecular weight of at least 1,000,000 or of less than 1,000,000, to yield a second composition for an active agent-free layer second layer, 
(1) najmanje jedne aktivne tvari, i (2) najmanje jednog polietilen oksida koji ima, bazirano na reološkim mjerenjima, približnu molekulsku težinu od najmanje 1,000,000, da se dobije prvi pripravak za prvi sloj sloja koji sadrži aktivnu tvar; HR P20150835 T1 (b) osiguravanje drugog pripravka koji sadrži najmanje jedan polietilen oksid koji ima, bazirano na reološkim mjerenjima, približnu molekulsku težinu od najmanje 1,000,000 ili od manje od 1,000,000, da se dobije drugi pripravak za drugi sloj koji ne sadrži aktivnu tvar u sloju,
wherein X, X1, and X2, are as defined in claim 1; 
II-a pri čemu X, x!, i x", su kako je definirano u zahtjevu 1;
The apparatus of claim 1, wherein the pneumatic release system decouples the conduit from the sending location and/or the receiving location. 
Uređaj prema zahtjevu 1, naznačen time da sustav pneumatskog otpuštanja (504, 508, 510, 512) odspaja vod (52) od mjesta slanja (10) i/ili mjesta prihvata (14).
a compound of formula (I) wherein when R8 is a methoxy group then neither R1 nor R3 is a radical, wherein R and R' are as defined above, 
spoj s formulom (I) pri čemu kada R8 je metoksi skupina tada ni R1 niti R3 je radikal, pri čemu R i R' su kako je definirano iznad,
This object is achieved by means of the features of the independent claims. 
Ovaj cilj postiže se pomoću svojstava neovisnog patentnog zahtjeva.
The compound of any one of claims 1-5, wherein: 
Tvar iz bilo kojeg od patentnih zahtjeva 1-5, gdje je:
The prodrug may be a compound of general formula (II): 
Spoj opće formule (II): RS 5 O=S5 N
The method according to claim 10, wherein the plasticizer amount is of 12% by weight of the total weight of the wet adhesive composition. 
Uporaba u skladu s patentnim zahtjevom 7, pri čemu navedeni sastavi sadrže količinu plastifikatora od 12% prema težini u odnosu na ukupnu težinu mokrih sastava.
Use according to any one of the preceding claims, characterized in that said 2-((1-methylpropyl)amino)ethanol is added to said suspension in an amount of from 500 to 15000 mg, preferably of from 1000 to 5000 mg, and more preferably of 1300 to 2000 mg, per liter of the aqueous phase of said suspension. 
Postupak u skladu s bilo kojim od prethodnih patentnih zahtjeva, naznačen time da je navedeni 2-((1-metilpropil)amino)etanol dodan u navedenu suspenziju u količini od 1000 do 5000 mg, poželjnije od 1300 do 2000 mg, po litri vodene faze navedene suspenzije.
Compound according to Claim 1, characterized in that X1 may be an alkyl group having from 1 to 4 carbon atoms, optionally substituted with one or more alkyl groups having from 1 to 3 carbon atoms, and X2 is an alkyl group having from 1 to 4 carbon atoms, optionally substituted with one or more alkyl groups having from 1 to 3 carbon atoms or one or more alkoxy groups having 1 or 2 carbon atoms. 
Spoj prema zahtjevu 1, naznačen time, da X1 i može biti alkil-skupina koja ima od 1 do 4 atoma ugljika, opcijski supstituirana s jednom ili više alkil-skupina koje imaju od 1 do 3 atoma ugljika, i X2 je alkil-skupina koja ima od 1 do 4 atoma ugljika, opcijski supstituirana s jednom ili više alkil-skupina koje imaju od 1 do 3 atoma ugljika ili jednu ili više alkoksi-skupina koje imaju 1 ili 2 atoma ugljika.